Company intelligence / Profile preview
Logix Biosciences
- Ownership
- Private
- Employees
- ~44
- Development stage
- Preclinical
Overview
Logix Biosciences is developing a pipeline of precision therapeutics focused on nasal immune modulation to prevent and treat allergies, infectious diseases, antimicrobial resistance, and related conditions. Their lead candidate LGX 242 is in preclinical development targeting allergies with broader potential applications. The company has demonstrated proof-of-concept with non-drug OTC nasal sprays but is advancing drug candidates through preclinical stages. They recently entered into an agreement with Mayo Clinic to advance their therapeutic programs for allergy relief, mutating infectious diseases, and antimicrobial resistance[2].
- Therapeutic areas
- PulmonologyImmunologyInfectious Diseases
- Modalities
- Non-steroidal immune modulatorsNasal sprays (non-drug OTC and drug candidates)
- Industry
- Biotech
Drug pipeline
2 assets1 more asset in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Logix Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Logix Biosciences.